168 related articles for article (PubMed ID: 31674290)
1. Refined homology model of cytochrome bcc complex B subunit for virtual screening of potential anti-tuberculosis agents.
Pan Z; Wang Y; Gu X; Wang J; Cheng M
J Biomol Struct Dyn; 2020 Oct; 38(16):4733-4745. PubMed ID: 31674290
[TBL] [Abstract][Full Text] [Related]
2. Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase-a molecular modelling perspective.
Tembe N; Machaba KE; Ndagi U; Kumalo HM; Mhlongo NN
J Mol Model; 2022 Jan; 28(2):35. PubMed ID: 35022913
[TBL] [Abstract][Full Text] [Related]
3. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
[TBL] [Abstract][Full Text] [Related]
4. Homology modeling and molecular docking simulation of some novel imidazo[1,2-a]pyridine-3-carboxamide (IPA) series as inhibitors of Mycobacterium tuberculosis.
Abdullahi M; Adeniji SE; Arthur DE; Haruna A
J Genet Eng Biotechnol; 2021 Jan; 19(1):12. PubMed ID: 33474593
[TBL] [Abstract][Full Text] [Related]
5. Identification of 4-Amino-Thieno[2,3-
Harrison GA; Mayer Bridwell AE; Singh M; Jayaraman K; Weiss LA; Kinsella RL; Aneke JS; Flentie K; Schene ME; Gaggioli M; Solomon SD; Wildman SA; Meyers MJ; Stallings CL
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511370
[TBL] [Abstract][Full Text] [Related]
6. QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents.
Bahuguna A; Rawat S; Rawat DS
Med Res Rev; 2021 Jul; 41(4):2565-2581. PubMed ID: 33400275
[TBL] [Abstract][Full Text] [Related]
7. Investigation of protein-ligand binding motions through protein conformational morphing and clustering of cytochrome bc1-aa3 super complex.
Sindhu T; Rajamanikandan S; Jeyakanthan J; Pal D
J Mol Graph Model; 2023 Jan; 118():108347. PubMed ID: 36208591
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.
Lu X; Williams Z; Hards K; Tang J; Cheung CY; Aung HL; Wang B; Liu Z; Hu X; Lenaerts A; Woolhiser L; Hastings C; Zhang X; Wang Z; Rhee K; Ding K; Zhang T; Cook GM
ACS Infect Dis; 2019 Feb; 5(2):239-249. PubMed ID: 30485737
[TBL] [Abstract][Full Text] [Related]
9. Structure-based discovery of phenyl-diketo acids derivatives as
Shukla R; Shukla H; Tripathi T
J Biomol Struct Dyn; 2021 May; 39(8):2945-2958. PubMed ID: 32306850
[No Abstract] [Full Text] [Related]
10. Virtual screening to identify novel potential inhibitors for Glutamine synthetase of
Kumari M; Subbarao N
J Biomol Struct Dyn; 2020 Oct; 38(17):5062-5080. PubMed ID: 31755360
[TBL] [Abstract][Full Text] [Related]
11. Computational insights into the binding pattern of mitochondrial calcium uniporter inhibitor through homology modeling, molecular dynamics simulation, binding free energy prediction and density functional theory calculation.
Duan N; Gao Z; Hu B; Ge D; Li W; Ye T; Geng X; Li X
J Biomol Struct Dyn; 2020 Oct; 38(17):5095-5107. PubMed ID: 31755365
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening.
Pandey P; Chatterjee S; Berida T; Doerksen RJ; Roy S
J Biomol Struct Dyn; 2022 Jul; 40(11):4832-4849. PubMed ID: 33353500
[TBL] [Abstract][Full Text] [Related]
13. Comparative modeling and dynamic simulation of UDP-N-acetylmuramoyl-alanine ligase (MurC) from Mycobacterium tuberculosis through virtual screening and toxicity analysis.
Isa MA
Life Sci; 2020 Dec; 262():118466. PubMed ID: 32961233
[TBL] [Abstract][Full Text] [Related]
14. Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.
Shelton C; McNeil M; Allen R; Flint L; Russell D; Berube B; Korkegian A; Ovechkina Y; Parish T
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0204121. PubMed ID: 35262374
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening.
Kumari M; Subbarao N
J Biomol Struct Dyn; 2022 Nov; 40(18):8185-8196. PubMed ID: 33826470
[TBL] [Abstract][Full Text] [Related]
16. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore model-based virtual screening, docking, biological evaluation and molecular dynamics simulations for inhibitors discovery against
Naz S; Farooq U; Khan S; Sarwar R; Mabkhot YN; Saeed M; Alsayari A; Muhsinah AB; Ul-Haq Z
J Biomol Struct Dyn; 2021 Feb; 39(2):610-620. PubMed ID: 31937192
[TBL] [Abstract][Full Text] [Related]
18. Ensemble-based high-throughput virtual screening of natural ligands using the Super Natural-II database against cell-wall protein dTDP-4-dehydrorhamnose reductase (RmlD) in
Ravichandran R; Ridzwan NFW; Mohamad SB
J Biomol Struct Dyn; 2022 Jul; 40(11):5069-5078. PubMed ID: 33382017
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cytochrome bc
Wani MA; Dhaked DK
Mol Divers; 2022 Oct; 26(5):2949-2965. PubMed ID: 34762234
[TBL] [Abstract][Full Text] [Related]
20. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
